14th Feb 2020 09:44
(Alliance News) - Yourgene Health PLC on Friday said Elucigene DPYD has been approved for sale in Australia as an in-vitro diagnostic, by the Therapeutic Goods Administration.
The Therapeutic Goods Administration is the regulatory body for therapeutic goods in Australia.
Elucigene is a genotyping test that can identify cancer patients with dihydropyrimidine dehydrogenase deficiency, the molecular diagnostics group said, adding that the deficiency can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil.
5-Fluorouracil is commonly used in the treatment of colon, oesophageal, stomach, pancreatic, breast and cervical cancer.
Yourgene said Elucigene will be sold through its Australian distribution partner Southern Cross.
"We are extremely pleased to address another market with our first oncology test which has already seen traction in the UK and Europe since its launch in September 2019. This reinforces our strategic plans of geographic expansion. We are looking forward to working with Southern Cross to be able to support oncologists and their patients in Australia with DYPD screening ahead of 5-FU treatment," said Yourgene Chief Executive Lyn Rees.
The stock was trading 1.0% up at 14.90 pence each on Friday morning in London.
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
YGEN.L